Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-13
2009-11-24
Shameem, Golam M M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S360100, C548S361100, C548S362500, C514S403000
Reexamination Certificate
active
07622493
ABSTRACT:
The present invention is directed to compounds of formula (I)wherein variables X1, X2, Y, R1a, R1b, R2a, R2b, A1, A2, A3, and A4are as defined in the description, and methods of use to treat pain, neuropathic pain, allodynia, pain associated with inflammation or an inflammatory disease, inflammatory hyperalgesia, bladder overactivity, and urinary incontinence.
REFERENCES:
patent: 5374643 (1994-12-01), Atwal et al.
patent: 2006/0128689 (2006-06-01), Gomtsyan et al.
patent: WO-03097586 (2003-11-01), None
patent: WO-2004078744 (2004-09-01), None
patent: WO-2007042906 (2007-04-01), None
patent: WO-2007050732 (2007-05-01), None
patent: WO-2008/110863 (2008-09-01), None
Caterina, M.J., et al., “The Vanilloid Receptor: A Molecular Gateway to the Pain Pathway”, Annu. Rev. Neurosci., vol. 24, pp. 487-517, 2001.
Caterina, M.J., et al., “The capsaicin receptor: a heat-activated ion channel in the pain pathway”, Nature, vol. 389, pp. 816-824, 1997.
Caterina, M.J., et al., “Impaired Nociception and Pain Sensation in Mice Lacking the Capsaicin Receptor”, Science, vol. 288, pp. 306-313, 2000.
Davis, J., et al., “Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia”, Nature, vol. 405, pp. 183-187.
Fowler, C., “Intravesical Treatment of Overactive Bladder”, Urology, vol. 55, pp. 60-64, 2000.
Hayes, et al., “Cloning and functional expression of a human orthologue of rat vanilloid receptor-1”, Pain, vol. 88, pp. 205-215, 2000.
Nolano, M., et al., “Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation”, Pain, vol. 81, pp. 135-145, 1999.
Pircio, et al., Eur. J. Pharmacol., vol. 31 (2), pp. 207-215, 1975.
Bognar Rezso et al. “Flavanoids XII. Synthesis of 4-ureldoflavan and bis (4flavanyl) urea”, ACTS Chim Acad. Sci, 1963, vol. 35, 223-224.
Collier et al. “The abdominal constriction response and its suppression by analgesic drugs in the mouse”, Br J Pharmac Chemother, 1968, vol. 32, 295-310.
Dade, J. “Synthesis of 2-Substituated Trifluoromethylquinolines for the Evaluation of Leishmanicidal Activity”, Chem Pharm Bull 2001, vol. 49 - Issue 4, 480-483.
Database Beilstein Beilstein Institute for Organic Chemistry, Frank Furt-Main, DE; XP002507218 Database accession No. brn 355828 abstract and Webster et al: J.Chem.Soc. , 1965, pp. 4785-4789.
International Search Report for application No. PCT/U52007/0066515, Mailed on Sep. 15, 2000, 3 pages.
International Search Report for application No. PCT/U505/042545, Mailed on Feb. 19, 2009, 3 pages.
Patani et al. “Bioisosterism: A Rational Approach in Drug Design”, Chemical Reviews, 1996, vol. 96, 3147-3176.
Brown Brian S.
Gomtsyan Arthur R.
Koenig John R.
Lee Chih-Hung
Abbott Laboratories
Shameem Golam M M
Srivastava Sonali S.
LandOfFree
Antagonists of the vanilloid receptor subtype 1 (VR1) and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonists of the vanilloid receptor subtype 1 (VR1) and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of the vanilloid receptor subtype 1 (VR1) and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4122688